MAPK3 and cancer: In fact, it has been demonstrated in cancer cells that co-targeting of the Ras/ERK1/2 and PI3K/AKT pathways with kinase inhibitors or genetic knockdown approaches targeting members of these pathways results in synthetic lethality30.